Highlights Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 19:04:51 13/03/2026 GMT			5-day change	1st Jan Change
0.4975 ^USD	-4.16%		-13.70%	-43.68%

03-03	Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-09	Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease	CI

Highlights

03-03	Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-09	Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease	CI
01-29	Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-16	Arch Biopartners Inc. Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide	CI
11-05	Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia	CI
17/09/25	Arch Biopartners Acquires Platform to Develop New Drugs Targeting Chronic Kidney Disease	MT
17/09/25	Arch Biopartners Inc. Acquires Pre-Clinical Platform Developing New Drugs to Treat Chronic Kidney Disease	CI
16/09/25	Arch Biopartners Inc. (OTCPK:ACHF.F) agreed to acquire Lipdro Therapeutics Inc. from Justin Chun for CAD 0.41 million.	CI
30/08/25	Arch Biopartners Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
06/08/25	Arch Biopartners Doses First Patient in Phase II Trial of LSALT Peptide	MT
06/08/25	Arch Biopartners Inc. Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury	CI
22/07/25	Arch Biopartners Inc. Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury	CI
31/05/25	Arch Biopartners Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025	CI
22/04/25	Arch Biopartners Inc. Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)	CI
05/03/25	Arch Biopartners to Raise $350,000 in Private Placement	MT
04/03/25	Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2024	CI
18/02/25	Arch Biopartners Receives No Objection Letter from Health Canada for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury	CI
29/01/25	Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2024	CI
08/01/25	Arch Biopartners Inc. Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)	CI
11/11/24	Arch Biopartners Begins Patient Dosing in Canada in Phase II Trial For LSALT Peptide	MT
11/11/24	Arch Biopartners Inc. Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	CI
11/09/24	Arch Biopartners Receives Approval From Alberta Health Services to Proceed with Phase II Trial	MT
11/09/24	Arch Biopartners Inc. Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury	CI
30/08/24	Arch Biopartners Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024	CI
02/08/24	Arch Biopartners' Drug Candidate Cilastatin Included in Phase II Trial Targeting Acute Kidney Injury	MT